INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $626,000 | +100.6% | 3,805 | +81.9% | 0.21% | +93.6% |
| Q4 2015 | $312,000 | +75.3% | 2,092 | +94.6% | 0.11% | +89.7% |
| Q3 2015 | $178,000 | -18.0% | 1,075 | +19.8% | 0.06% | -20.5% |
| Q2 2015 | $217,000 | -65.9% | 897 | -66.6% | 0.07% | -66.0% |
| Q3 2014 | $636,000 | +63.1% | 2,689 | +63.1% | 0.22% | +77.7% |
| Q2 2014 | $390,000 | +87.5% | 1,649 | +161.3% | 0.12% | +80.6% |
| Q1 2014 | $208,000 | – | 631 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |